Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)
Christopher M. Booth(Queen's University), Elizabeth A. Eisenhauer(Queen's University), Marinus W. Lobbezoo, Giuseppe Giaccone(Cornell University), Lesley Seymour(Queen's University), A. Hilary Calvert(Newcastle University)
Cited by 109
Related Papers
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
|JAMA|2003|1.4k
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2009|913